LUND, SWEDEN--(Marketwired - April 15, 2013) - Active Biotech's Annual Report 2012 (in
Swedish) is now available for download
at www.activebiotech.com. The English version will be available within
The Annual Report will only be digitally distributed.
Lund, April 15, 2013
Active Biotech AB (publ)
President & CEO
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal
are laquinimod, an orally administered small molecule with
immunomodulatory properties for the treatment of multiple sclerosis,
for prostate cancer and ANYARA primarily for the treatment of renal cell
In addition, laquinimod is in Phase II development for Crohn's and
company also has one additional project in clinical development, the
administered compound 57-57 for Systemic Sclerosis. Please
www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is required under the Financial Instruments Trading Act to
the information in this press release public. The information was submitted
publication at 10:00 a.m. CET on April 15, 2013.
Annual Report 2012 Active Biotech AB (publ):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE